The potential clinical implications of targeted therapies for DLBCL and why the situation is complex
iwNHL 2016 highlights: CAR T-cell therapy, DLBCL and new technologies
Update on the clinical management of diffuse large B-cell lymphoma
Christian Gisselbrecht et al.
Six-month analysis of tisagenlecleucel in stubborn form of lymphoma shows sustained responses
Stephen J. Schuster
The next steps for TGR-1202 and targeting the gene c-Myc